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Purpose: To evaluate the possible role of the VSX1 gene in a group of patients from the Indian subcontinent with
keratoconus.
Methods: Molecular analysis of 66 patients with a diagnosis of keratoconus, based on clinical examination and corneal
topography, was carried out. DNA extraction from peripheral blood followed by Polymerase Chain Reaction (PCR)
amplification of the VSX1 gene was performed. The entire coding region and the exon–intron junctions of the VSX1 gene
were analyzed by direct sequencing.
Results: A novel change at c.525G>C, replacing amino acid glutamine at position 175 with histidine, was found in one
affected individual. One of the previously reported SNPs (rs12480307) was found with equal frequency in both patients
and controls.
Conclusions: This is the first report from the Indian subcontinent exploring the role of VSX1 in the causation of
keratoconus. One novel mutation (Q175H) predicted to be a potentially damaging change was seen in an affected
individual; this substantiates the importance of this gene but its precise role in disease causation needs further investigation.
Keratoconus is a bilateral, noninflammatory, gradually
progressive  corneal  disorder  characterized  by  progressive
thinning  and  steepening  of  the  central  cornea.  It  usually
appears during teenage years, the common symptoms being
myopia and astigmatism, and it is one of the major indications
for corneal transplantation [1,2].
Keratoconus normally occurs as a sporadic disorder, but
both genetic and environmental factors seem to play a role in
its causation [3]. A strong family history has been documented
in about 6%–10% of patients with both autosomal and X-
linked mode of inheritance [4,5]. Its prevalence in first-degree
relatives is 13.5% [6] which is between 15 and 64 times higher
than  for  the  general  population  [7].  The  etiology  of
keratoconus is unknown. It arises as an isolated defect but is
also known to be associated with conditions such as Ehler–
Danlos, Marfan, Apert, Noonan, and Downs Syndrome.
Genome-wide linkage analyses have identified several
chromosomal loci and genes that may be associated with
keratoconus [8-12]; however, some were eventually excluded
[13,14] while for others a conclusive association with the
disease is yet to be established. Mutations in AIPL1,CRB1,
and  CRX  have  been  implicated  in  patients  with  Leber
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congenital  amaurosis,  rendering  them  susceptible  to
keratoconus [15,16].
One  of  the  strongly  implicated  candidate  genes  for
keratoconus is Visual System Homeobox 1 (VSX1) localized
to 20p11-q11. Initially this gene was chosen for screening
mutations  exploring  the  association  between  posterior
polymorphous corneal dystrophy (PPCD) and keratoconus
[12]. VSX1 is a developmental gene considered important in
ocular  development  and  is  normally  expressed  in  the
developing cornea. VSX1 mRNA has been found in the outer
tier of the inner nuclear layer of the human retina, embryonic
craniofacial tissue and the cornea [17]. The gene has 5 exons
spanning 6.2 kb of coding sequence [12]. Several genetic
variants of the VSX1 gene [12,18–23] have been reported from
various parts of the world but a definite pathogenic role of the
genetic  variants  in  causation  of  keratoconus  is  not  yet
established.
The  VSXI  variants  include  D144E,  G160D,  P247R,
L159M, R166W, H244R, L17P, G160V and N151S (Table 1)
which  were  initially  reported  as  pathogenic  but  whose
pathogenicity could not be confirmed because segregation of
these variants was seen in unaffected individuals also. He´on
et al. [12] identified a compound heterozygous change with
P247R and G160D and reported G160D to be pathogenic and
P247R to be nonpathogenic. Another study [18] reported just
the opposite, where P247R was found to be co-segregating
with  keratoconus.  The  D144E  mutation  was  reported  as
pathogenic [18,22] in earlier studies but subsequent studies
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2475identified its presence in unaffected individuals and suggested
this  to  be  a  polymorphism  [19,20].  The  variants  R166W,
H244R  and  L159M  have  been  identified  in  keratoconus
patients but these changes did not segregate with the disease
phenotype  in  their  family  members  and  hence  were  not
considered sufficiently significant to support a pathogenic
role  in  keratoconus  [21].  Similarly,  variants  G160V  and
N151S  have  been  identified  in  patients  from  the  Korean
population [23] but these changes have not been reported from
other populations.
The present study was undertaken in order to search for
genetic variations of the VSX1 gene in the Indian population
and to explore its role in causation of keratoconus. Mutational
analysis  of  VSX1  was  carried  out  in  66  unrelated  Indian
patients  affected  with  keratoconus  in  comparison  to  100
controls.
METHODS
Patients affected with keratoconus seen in the Cornea and
Refractive Surgeries Services and Contact Lens Clinic at Dr.
Rajendra Prasad Centre for Ophthalmic Sciences, All India
Institute of Medical Sciences, during the period of March
2007 to 2008 were included in the study. The study adhered
to the tenets of the Declaration of Helsinki and was approved
by the Institutional Ethics Committee. Informed consent was
taken from all the patients before being enrolled for the present
study. Detailed family histories up to three generations were
taken and pedigree charts were constructed. History of ocular
or other hereditary disorders was recorded. The existence of
consanguinity and the regional birthplace of patients were also
noted.
A total of 66 unrelated patients with keratoconus were
recruited in the present study: 23 females and 43 males, with
41  patients  (62%)  aged  between  10  and  20.  The  patients
presented with deterioration of vision and were diagnosed
based on clinical features, such as stromal thinning, Vogt’s
striae,  Fleischer’s  ring,  Munson’s  sign,  and  corneal
topography. Topographical features, such as corneal power
(K), inferior–superior dioptric asymmetry (I-S), astigmatism
(Ast), and skewed radial axis (SRAX) were used to calculate
KISA%  (a  single  index  that  quantifies  the  irregularity  of
corneal  shape  and  presence  of  astigmatism,  typical  of
keratoconus, with good clinical correlation). A total of 100
healthy volunteers with no ocular or other disorders matched
for age and gender formed the controls. A peripheral blood
sample (5 ml) was collected from all the patients and control
subjects after taking informed consent and explaining the
nature and possible consequences of study participation.
DNA extraction and PCR amplification: Genomic DNA
was  extracted  from  peripheral  blood  leukocytes  using
standard  protocols.  All  the  five  exons  and  intron/exon
boundaries of VSX1 were amplified using custom-synthesized
oligonucleotide primers as described previously [12]. Each
reaction was carried out in a 25 μl mixture containing 2.5 μl
10X PCR buffer with 3.5 mM MgCl2, 2.5 mM dNTPs, 10 pM
of each primer, 0.7 U Taq DNA polymerase (Roche) and 100
ng  genomic  DNA.  Thermal  cycling  was  performed  in  a
thermal cycler (Applied Biosystem 9700) as described: initial





Pathogenic /non pathogenic Total number of patients studied Mutation seen in individuals /
families
Source
1 L17P Pathogenic 80 5 /3 [18]
2 D144E Pathogenic 80 6/2 [18]
Pathogenic Ashkenazi Jewish family [22]
No familial segregation 85 F 4 (2 [A]; 2 [UA]) /1 [20]
Non pathogenic 100 1/1 [19]
Pathogenic/Non pathogenic??? 63Kc+90G 2/1 [12]
3 L159 M Pathogenic(not conserved) 63Kc+90G 4/1 [12]
Non pathogenic 521 6 (3 [A] ; 2 [UA]; 1 [C]/- [21]
4 N151S Pathogenic 249 1/1 [23]
5 G160D Non pathogenic 80 4/2 [18]
Identified in PPD not in Keratoconus & not
conserved
63 5/1 [12]
6 G160V Pathogenic 249 13/- [23]
7 R166W Pathogenic 63Kc+90G 1/1 [12]
Non pathogenic 521 NVI [21]
8 H244R Pathogenic/non pathogenic??(seen in
controls)
63Kc+90G 3/1 [12]
Non pathogenic 521 3 (2[A], 1[UA])/- [21]
9 P247R Pathogenic 80 4 /1 [18]
Non pathogenic 63Kc+90G 2/1 [12]
Identified in controls/ non pathogenic 85 F 1/1 [C] [20]
Table 1 shows the sequence variants identified by various authors and the conclusions reached regarding their pathogenecity.
‘F’ represents families, ‘Kc’ represents patients with keratoconus, ‘G’ represents patients with glaucoma,’ A’ represents variants
identified in patients affected with keratoconus, ‘UA’ represents variants identified in unaffected relatives of keratoconus
patients, ‘C’ represents variants identified in controls and ‘NVI’ represents no variants identified.
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62 °C (exons 1–4) or 60 °C (exon 5) for 30 s, 72 °C for 30 s,
and a final extension for 10 min at 72 °C.
DNA  Sequencing:  All  the  amplified  products  were
sequenced  bidirectionally  using  BigDye  Terminator  Mix
version 3.1 (Applied Biosystems [ABI], Foster City, CA)
according  to  the  manufacturer’s  instructions  and  were
analyzed  on  an  ABI-3100  Genetic  Analyzer  (ABI).
Nucleotide  sequences  were  compared  with  the  published
VSX1 cDNA sequence (GenBank NM_014588).
SIFT and PolyPhen analysis: The potential impact of the
amino acid change was assessed with the SIFT analysis tool
(Sorting Intolerant From Tolerant) and PolyPhen analysis.
These  tools  produce  a  multiple  sequence  alignment  from
different species of a gene to assess the positions of conserved
amino acids and analyze the effect of missense changes on the
conserved structure of proteins. The SIFT tool assigns a score
to the mutations and a score of <0.05 is considered potentially
damaging. PolyPhen analysis uses PSIC software (Position-
Specific  Independent  Counts)  to  calculate  profile  scores
(PSIC scores) that are logarithmic ratios of the likelihood of
a given amino acid occurring at a particular position to the
likelihood  of  this  amino  acid  occurring  at  any  position
(background frequency).
RESULTS
The mean age at onset of symptoms among the patients was
18 years. Consanguinity was not present in any of the cases
recruited for the present study. The patients were analyzed for
the  presence  of  mutations  in  all  the  five  exons  of  VSX1.
Among  the  patients  under  study  a  novel  heterozygous
nucleotide change c.525G>C (Q175H; GenBank GU138372;
ACZ01961) was identified in one individual. The presence of
this  change  was  confirmed  by  a  repeat  bidirectional
sequencing (Figure 1). No similar change was found in any of
the 100 normal controls studied. SIFT tool analysis revealed
a score of <0.05 and PolyPhen analysis gave a PSIC score
difference of 1.896; both tools predicted that the replaced
amino acid would be potentially damaging and would not be
tolerated.  The  amino  acid  glutamine  at  position  175  is
important and has been conserved throughout the orthologs
(Figure 2). A previously reported SNP rs12480307 was also
identified in four patients and six controls, segregating with
equal frequency in both groups.
DISCUSSION
In the present study we identified a novel heterozygous change
c.525G>C (Q175H; GenBank GU138372; ACZ01961) in an
affected  individual.  SIFT  tool  and  PolyPhen  analyses
predicted that the mutation Q175H (replacing amino acid
glutamine with histidine) could be damaging. The absence of
this  change  in  100  controls  is  suggestive  of  it  being
pathogenic. VSX1 has previously been implicated in causation
of keratoconus according to earlier reports; these established
that keratoconus and posterior polymorphic corneal dystrophy
are co-localized within the chromosome 20p11-q11 region
[12] and identified four sequence variants, two of which were
considered pathogenic. To date, several genetic variants of the
VSX1  gene  have  been  reported  (Table  1)  but  their
pathogenicity  could  not  always  be  confirmed  because
segregation of these variants was also seen in some unaffected
individuals.  Q175H  is  a  novel  mutation,  identified  in  the
present  study,  adding  to  the  database  of  mutations  in  the
VSX1 gene and supporting its role in keratoconus. However,
Figure 1. Partial nucleotide sequence of VSX1 exon 3. Partial exon 3
nucleotide  sequence  of  VSX1  showing  G→C  transition  in  the
mutated allele of the patient (P) in comparison to control (C). RP
represents a partial chromatogram of the reverse nucleotide sequence
of the patient in comparison to control (RC). The arrow-head shows
the position of the change in the given sequences.
Figure 2. Multiple sequence alignment of the amino acid sequences
of VSX1 in different species. The highlighted amino acid glutamine
(Q) shown in red at position 175 is conserved in all the orthologs.
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be a minor gene and its exact role during development needs
to be documented.
VSX1 expression is detected in adult retinal and corneal
tissue and in embryonic craniofacial tissue [24,25]. The gene
is a member of the CVC domain containing a paired-like class
of homeodomains (HD) which play a role in craniofacial and
ocular development [26]. The homeodomain region folds into
three alpha helices; the latter two bind DNA in the major
groove of the double helix and the third is the recognition helix
that is responsible for amino acids making contact with the
DNA bases. The Q175H change is present in the HD region
of VSX1, where a neutral amino acid is replaced by a polar
one. This may affect the binding of VSX1 protein with the
DNA  and  modify  the  transcription  rate.  The  onset  for
keratoconus is typically seen around the teenage years and so
its role in normal eye development cannot be ruled out. In the
light of previous studies, there is still insufficient evidence for
the pathogenic role of VSX1 alone in causation of keratoconus.
However, in our study potentially damaging mutation was
detected, although only in 1.6% of the patients. Recently,
CRB1 mutations were found to be associated with keratoconus
in patients with Leber Congenital Amaurosis; in this case the
authors  suggested  that  the  CRB1  mutations  could  make
patients  more  susceptible  to  developing  keratoconus  [15].
Therefore, the VSX1 gene might have a small effect by itself,
yet operate in conjunction with other genes or environmental
factors in causation of keratoconus.
To conclude, to the best of our knowledge this is the first
report from the Indian subcontinent exploring the causative
role of the VSX1 gene in keratoconus. We have identified one
novel  mutation,  Q175H,  predicted  to  cause  a  pathogenic
change which would not be tolerated. This study adds one
novel pathogenic mutation to the existing repertoire of VSX1
mutations but its wider role still needs to be explored.
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